高级别浆液性卵巢癌患者原发肿瘤及配对循环肿瘤DNA中的ESR1甲基化
本研究采用高特异性高灵敏度实时甲基化特异性PCR检测高级别浆液性卵巢癌(HGSC)原发肿瘤及配对血浆循环肿瘤DNA(ctDNA)中ESR1甲基化状态。A组66例原发肿瘤中32例(48.5%)检出ESR1甲基化,B组53例原发肿瘤中15例(28.3%)检出,B组50例配对血浆中19例(38.0%)检出。原发肿瘤与配对血浆ctDNA的ESR1甲基化一致性有统计学意义(P=0.004),B组原发肿瘤ESR1甲基化与更好的总生存(P=0.027)和无进展生存(P=0.041)相关。
要点
- HGSC原发肿瘤及配对血浆ctDNA中均可检出ESR1甲基化。
- 原发肿瘤与配对血浆ctDNA的ESR1甲基化一致性有统计学意义(P=0.004)。
- B组原发肿瘤ESR1甲基化与更好的总生存(P=0.027)和无进展生存(P=0.041)相关。
核心结论
- 首次报告HGSC患者血浆ctDNA中存在ESR1甲基化。
- 原发肿瘤与配对ctDNA的ESR1甲基化一致性有统计学意义。
- 结果提示ESR1甲基化与HGSC患者更好的临床结局相关。
研究设计与样本
- 采用高特异性高灵敏度实时甲基化特异性PCR检测ESR1甲基化。
- A组为66例原发肿瘤;B组为53例原发肿瘤及50例配对血浆样本。
主要发现
- A组原发肿瘤ESR1甲基化为32/66(48.5%)。
- B组原发肿瘤ESR1甲基化为15/53(28.3%)。
- B组配对血浆样本ESR1甲基化为19/50(38.0%)。
- 原发肿瘤与配对血浆ctDNA的ESR1甲基化一致性P=0.004。
- B组原发肿瘤ESR1甲基化与更好的总生存(P=0.027)和无进展生存(P=0.041)相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Estrogen receptor, coded by the ESR1 gene, is highly expressed in epithelial ovarian cancer. ESR1 gene is frequently methylated in many types of gynecological malignancies. However, only a few studies attempted to investigate the role of ESR1 methylation and its clinical significance in ovarian cancer so far. The aim of our study was to examine ESR1 methylation status in primary tumors and corresponding circulating tumor DNA of patients with high-grade serous ovarian cancer (HGSC). METHODS: ESR1 methylation was detected by a highly specific and sensitive real-time methylation-specific PCR assay. Two groups of HGSC samples were analyzed: group A (n = 66 primary tumors) and group B (n = 53 primary tumors and 50 corresponding plasma samples). RESULTS: ESR1 was found methylated in both groups of primary tumors: in 32/66 (48.5%) of group A and in 15/53 (28.3%) of group B. 19/50 (38.0%) corresponding plasma samples of group B were also methylated for ESR1. A significant agreement for ESR1 methylation was observed between primary tumors and paired plasma ctDNA samples (P = 0.004). Interestingly, the presence of ESR1 methylation in primary tumor samples of group B was significantly correlated with a better overall survival (P = 0.027) and progression-free survival (P = 0.041). CONCLUSIONS: We report for the first time the presence of ESR1 methylation in plasma ctDNA of patients with HGSC. The agreement between ESR1 methylation in primary tumors and paired ctDNA is statistically significant. Our results indicate a correlation between the presence of ESR1 methylation and a better clinical outcome in HGSC patients.
引用
- Giannopoulou L, Mastoraki S, Buderath P, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018. PMID: 29807696. doi:10.1016/j.ygyno.2018.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。